SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study for Pancreatic Cancer
- First dose at HOAG Health in FAPI-PRO trial for Pancreatic Ductal Adenocarcinoma
- A parallel […]
Presented by: Sherly Mosessian, PhD, Chief Scientific Officer, SOFIE
8th Theranostics World Congress; Cape Town, South […]
Seven SOFIE radiopharmacies now produce the FAP-targeting radiopharmaceutical, as SOFIE launches Phase 3 clinical trials […]
Results from SOFIE’s Phase 2 diagnostic study on [18F]FAPI-74 PET were presented to the oncological […]
FAPI-PRO is a GO!
SOFIE is proud to announce FAPI-PRO, our [18F]FAPI-74 Phase 3 study on […]
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI […]
Another defining moment for SOFIE Biosciences!
Last Friday, November 14, 2025, FAPI-GO, SOFIE’s [18F]FAPI-74 Phase 3 […]
Sherly Mosessian, PhD, SOFIE’s Chief Scientific Officer, has been recognized by the […]
Adrien Holzgreve, Lena M Unterrainer, Kimberly Flores, Ethan C Lam, Christine E Mona, Johannes Czernin, […]